Key Drivers
- High gross margins
- Heavy opex burn
- High financial leverage
AIAI Summary
Treat TVTX as a commercial-growth, margin-leverage investment—its valuation now hinges on continued rapid FILSPARI uptake and a favorable FSGS PDUFA outcome rather than binary R&D milestones. Monitor quarterly FILSPARI net sales/gross‑to‑net trends, upcoming PDUFA/label/REMS developments, and near‑term cash‑flow vs. debt/refinancing needs—failure on any of these fronts would likely trigger sharp downside given high leverage and premium multiples.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Heavy opex burn
- •High financial leverage
TVTX reported a FY net loss driven by outsized R&D/SG&A and heavy leverage despite Q4 profitability and strong free cash flow, leaving liquidity adequate but valuation notably rich.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Range-bound tests
TVTX has declined about 11% over the last month into a clear short-term downtrend, with rallies stalling near $30.7–$30.9 and key support around $26.9–$27.3 that will dictate whether further downside follows.
~11% drop over the last month signaling sustained short-term weakness
Sentiment & News
Key News Insights:
- •FILSPARI acceleration
- •Profitability improving
- •April PDUFA
Travere's FY25 results show FILSPARI‑driven revenue momentum (FY25 revenue +81%, FILSPARI +144%) with improving profitability and a material April 2026 PDUFA for FSGS that could further boost near‑term outlook.
Strong commercial execution and upcoming FSGS regulatory risk/reward make Travere a more buyable growth‑with‑profitability story into April
Similar Companies in Healthcare
Other companies in the same sector with AI ratings